Scientific Advisory Board

Endocrinology  |  Metabolic Surgery  |  Gastroenterology  |  Internal Medicine

GI Dynamics is privileged to have as our scientific advisors a prestigious, multidisciplinary group of leaders dedicated to advancing research for the treatment of type 2 diabetes, obesity and other metabolic disorders.


David E. Cummings, MD

Endocrinologist, Washington, DC, U.S.A

“I’m very excited to join the team at GI Dynamics and help move EndoBarrier forward,” said Cummings. “This novel device has strong potential to recapitulate some of the magic of bariatric/metabolic operations for type 2 diabetes and obesity without the invasiveness of surgery.”

Carel le Roux, MD, PhD

Endocrinologist, Dublin, Ireland

“Type 2 diabetes remains one of the most challenging chronic diseases people struggle with. Novel and scalable treatments that can have a positive impact on people’s lives are urgently needed,” said Le Roux. “EndoBarrier has broken the mold of how we used to think about novel treatments for diabetes.”

Metabolic Surgery

Ricardo Cohen, MD

Bariatric / Metabolic Surgeon, Sao Paulo, Brazil

“GI Dynamics with EndoBarrier has produced an excellent adjuvant tool to achieve diabetes control,” said Dr. Cohen. “I look forward to helping GI Dynamics continue to develop EndoBarrier to provide a safe and effective device in a treatment area that is growing rapidly.”

Jan Willem Greve, MD, PhD

Bariatric / Metabolic Surgeon, Heerlen, Netherlands

“Obesity and its co-morbidities are an immense challenge for modern health care,” said Greve. “Bariatric or metabolic surgery is a proven tool to treat morbidly obese patients with type 2 diabetes. However, the majority of these patients may have a BMI that is too low or have serious contraindications that preclude them from being candidates for such an invasive surgical procedure. As a bariatric / metabolic surgeon, I believe EndoBarrier is a powerful addition to our treatment armamentarium.”

Francesco Rubino, MD

Bariatric / Metabolic Surgeon, London, UK

“The potential impact of EndoBarrier for the treatment of both type 2 diabetes and obesity in less obese patients is truly exciting. I look forward to working with the GI Dynamics SAB to further study EndoBarrier and its many benefits for patients.”

Philip Schauer, MD

Bariatric / Metabolic Surgeon, Cleveland, OH, U.S.A.

“EndoBarrier is bridging the gap in care for patients struggling to control their HbA1c levels with ever-increasing doses of insulin but do not meet the criteria for gastric bypass surgery. I am excited to help advance the tools that will provide a powerful treatment option for this patient population.”


Gerald Holtmann, MD

Gastroenterologist, Brisbane, Australia

“With my current research focused on the role of gut microbiome and brain¬–gut interactions, I’m excited to contribute to the GI Dynamics SAB,” said Dr. Holtmann. “Understanding the role of EndoBarrier should produce interesting research that will hopefully help patients.”

Manoel Galvao Neto, MD

Gastroenterologist, Sao Paulo, Brazil

“Since my first-in-human EndoBarrier implant in 2005, I have seen the health benefit it offers to patients in need of an alternative treatment,” said Galvao. “I truly believe EndoBarrier fills the existing type 2 diabetes treatment gap.”

Thomas Rösch, MD

Gastroenterologist, Hamburg, Germany

“The innovation of endoscopic procedures continues to advance treatments in many disease states,” said Dr. Rösch. “By being part of the GI Dynamics Scientific Advisory Board, I will have the opportunity to help understand these innovations and hopefully advance treatment for the many people diagnosed with obesity and type 2 diabetes.”

Judith Korner, MD, PhD

Endocrinologist, New York, NY, U.S.A

“Our research has shown there is a need for new treatment options for type 2 diabetes and obesity as we see rates continue to rise throughout the world. Specifically, we have shown that despite significant effort to optimize lifestyle and dietary counseling in conjunction with the utilization of diabetes medication, significant limitations exist that can be addressed with innovative interventional approaches. I am eager to aid in the development of EndoBarrier with GI Dynamics and the SAB as it has shown promising results.”

Internal Medicine

Allon Friedman, MD

Internal Medicine, Indianapolis, IN, U.S.A.

“I am pleased to work with GI Dynamics in broadening their focus to include CKD. I look forward to working with this talented group of clinicians on the GI Dynamics SAB and achieving my goal of improving patient outcomes in the important and ever-growing field of type 2 diabetes- and obesity-related kidney disorders.”

Steven Opal, MD

Internal Medicine, Indianapolis, IN, U.S.A.

“I am honored to sit among such a prestigious group of clinicians on the GI Dynamics Scientific Advisory Board. I look forward to aiding in the advancement of EndoBarrier and helping to bring this technology to patients effected by type 2 diabetes and obesity.”